Analytical Method Validation for Estimation of Neurotransmitters (Biogenic Monoamines) from Cerebrospinal Fluid Using High Performance Liquid Chromatography

被引:10
作者
Lokhande, Rohan V. [1 ,2 ]
Bhagure, Ganesh R. [2 ]
Dherai, Alpa J. [1 ]
Naik, Prasad R. [1 ]
Udani, Vrajesh P. [3 ]
Desai, Neelu A. [3 ]
Ashavaid, Tester F. [1 ]
机构
[1] PD Hinduja Hosp & MRC, Dept Lab Med, Biochem Sect, Mumbai, Maharashtra, India
[2] Satish Pradhan Dnyanasadhana Coll, Dept Chem, Thana, India
[3] PD Hinduja Hosp & MRC, Dept Paediat Neurol, Mumbai, Maharashtra, India
关键词
Cerebrospinal fluid; Biogenic monoamine; HPLC; Validation; Abnormal neurotransmitter; DISORDERS;
D O I
10.1007/s12291-020-00949-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biogenic amine neurotransmitters such as serotonin and dopamine are essential for signaling in both central and peripheral nervous system. Their metabolism is a multistep pathway and any defect in this results in alteration in metabolites of serotonin 5-Hydroxyindole acetic acid (5HIAA) and dopamine homovanillic acid (HVA) and 3-O-Methyl Dopa (3-OMD). Estimation of these metabolites in cerebrospinal fluid (CSF) assists in diagnosis of neurotransmitter defects. Their estimation is technically demanding and is currently available only in referral centers. We aimed to optimize a method for analysis of 5HIAA, HVA and 3-OMD. A high performance liquid chromatography (HPLC) method with electro chemical detector (ECD) was standardized for estimation. Analysis for method validation, reference range verification and clinical correlation was performed. Linearity obtained for 5-HIAA, HVA and 3-OMD was 65.35-2615.0 nmoles/l, 68.62-2745.0 nmoles/l and 236.5-4730.0 nmoles/l respectively. The coefficient of variation for internal quality controls ranged from 5 to 14% and the external proficiency testing samples (n = 16) were within peer group range. CSF metabolite levels of samples for reference range analysis overlapped with age matched ranges reported in literature. Among the 40 suspected patients analyzed for clinical testing four were found to have a neurotransmitter defect. These patients were then confirmed with molecular testing and clinical correlation. The method is validated and can be adapted in a clinical laboratory with analytical competence in HPLC.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 18 条
  • [1] World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20): : 2191 - 2194
  • [2] [Anonymous], 1995, CPMP/ICH/381/95,
  • [3] [Anonymous], 2018, ENCY BRIT ENC BRIT O
  • [4] [Anonymous], 2011, EMEACHMPEWP192217200
  • [5] Analysis of human cerebrospinal fluid monoamines and their cofactors by HPLC
    Batllori, Marta
    Molero-Luis, Marta
    Ormazabal, Aida
    Casado, Mercedes
    Sierra, Cristina
    Garcia-Cazorla, Angels
    Kurian, Manju
    Pope, Simon
    Heales, Simon J.
    Artuch, Rafael
    [J]. NATURE PROTOCOLS, 2017, 12 (11) : 2359 - 2375
  • [6] Blau N., 1996, PHYS GUIDE LAB DIAGN, VFirst, P79
  • [7] Burlina A B, 2017, EJIFCC, V28, P64
  • [8] Monoamine neurotransmitters and movement disorders in children and adults
    Doummar, D.
    Moussa, F.
    Nougues, M. -C.
    Ravelli, C.
    Louha, M.
    Whalen, S.
    Burglen, L.
    Rodriguez, D.
    de Villemeur, T. Billette
    [J]. REVUE NEUROLOGIQUE, 2018, 174 (09) : 581 - 588
  • [9] Review: The Application of Liquid Chromatography Electrochemical Detection for the Determination of Drugs of Abuse
    Honeychurch, Kevin
    [J]. SEPARATIONS, 2016, 3 (04):
  • [10] Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid
    Hyland, Keith
    [J]. CLINICAL CHEMISTRY, 2008, 54 (04) : 633 - 641